RZLT Stock Forecast 2025-2026
Distance to RZLT Price Targets
RZLT Price Momentum
10 Quality Stocks Worth Considering Now
Researching Rezolute (RZLT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on RZLT and similar high-potential opportunities.
Latest RZLT Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, RZLT has a bullish consensus with a median price target of $13.00 (ranging from $9.00 to $16.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $2.73, the median forecast implies a 376.2% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Jason Butler at JMP Securities, suggesting a 229.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RZLT Analyst Ratings
RZLT Price Target Range
Latest RZLT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RZLT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 13, 2025 | JMP Securities | Jason Butler | Market Outperform | Maintains | $9.00 |
| Feb 13, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $14.00 |
| Feb 10, 2025 | Guggenheim | Debjit Chattopadhyay | Buy | Reiterates | $0.00 |
| Feb 5, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $14.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $14.00 |
| Nov 5, 2024 | Wedbush | Yun Zhong | Outperform | Initiates | $12.00 |
| Sep 27, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $14.00 |
| Sep 20, 2024 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $7.00 |
| Sep 10, 2024 | BTIG | Julian Harrison | Buy | Maintains | $15.00 |
| Sep 9, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $14.00 |
| Aug 27, 2024 | Guggenheim | Debjit Chattopadhyay | Buy | Initiates | $11.00 |
| Aug 6, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $14.00 |
| Aug 6, 2024 | Maxim Group | Jason McCarthy | Buy | Maintains | $10.00 |
| Jul 17, 2024 | BTIG | Julian Harrison | Buy | Initiates | $13.00 |
| Jun 4, 2024 | Craig-Hallum | Christian Schwab | Buy | Initiates | $14.00 |
| May 22, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $14.00 |
| May 16, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $14.00 |
| Apr 19, 2024 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $7.00 |
| Apr 18, 2024 | JonesTrading | Catherine Novack | Buy | Initiates | $10.00 |
| Apr 18, 2024 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $7.00 |
Rezolute, Inc. (RZLT) Competitors
The following stocks are similar to Rezolute based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Rezolute, Inc. (RZLT) Financial Data
Rezolute, Inc. has a market capitalization of $165.26M with a P/E ratio of -2.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -74.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Rezolute, Inc. (RZLT) Business Model
About Rezolute, Inc.
Develops therapeutics for metabolic and liver diseases.
Rezolute, Inc. operates in the biotechnology sector, focusing on the research and development of novel therapeutics aimed at treating chronic metabolic diseases and rare liver disorders. The company generates revenue by advancing its innovative pipeline of therapies through clinical trials and eventual commercialization of successful treatments.
The company targets significant unmet medical needs, particularly in orphan indications, which may provide breakthrough therapies for conditions lacking effective treatments. Rezolute's advancements in healthcare could potentially enhance patient quality of life and influence treatment protocols within the pharmaceutical market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
64
CEO
Mr. Nevan Charles Elam J.D.
Country
United States
IPO Year
2012
Website
www.rezolutebio.comRezolute, Inc. (RZLT) Latest News & Analysis
Rezolute (RZLT) has formed a hammer chart pattern, suggesting potential support. Additionally, upward revisions in earnings estimates may indicate a possible trend reversal.
The hammer pattern indicates potential support for Rezolute (RZLT), suggesting a possible trend reversal, while rising earnings estimates may attract bullish sentiment among investors.
Rezolute, a microcap biopharma with a $279M market cap, is developing therapies for hyperinsulinism. RZ358 shows promise in late-stage trials. The company has $105M in cash, with a runway of 5-7 quarters.
Rezolute's promising late-stage trials and strong cash position suggest potential growth and value appreciation, making it an attractive option for investors in the biopharma sector.
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
1 month agoErsodetug, a new human monoclonal antibody for hyperinsulinism, has been granted Breakthrough Therapy and Orphan Drug Designations.
Ersodetug's designations may accelerate its development and approval, potentially leading to significant market opportunities and revenue growth for the company.
Rezolute is advancing its lead candidate, ersodetug (RZ358), through strong clinical development for treating hypoglycemia related to hyperinsulinism.
Rezolute's strong clinical progress with RZ358 enhances its growth potential, impacting its stock value and attracting investor interest in biotechnology.
A Data Monitoring Committee reviewed the open-label arm for infants under 1 year old, confirming that target drug concentrations were safely achieved at the tested doses.
The DMC's review indicates safety and efficacy in infants for the drug, potentially leading to positive outcomes in regulatory approval and market opportunities, impacting stock performance.
Rezolute, Inc. (Nasdaq: RZLT) will participate in the Guggenheim SMID Cap Biotech Conference on February 5-6, 2025, focusing on therapies for rare diseases.
Rezolute's participation in a key biotech conference signals its commitment to growth and visibility in the market, potentially attracting investor interest and impacting stock performance.
Frequently Asked Questions About RZLT Stock
What is Rezolute, Inc.'s (RZLT) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Rezolute, Inc. (RZLT) has a median price target of $13.00. The highest price target is $16.00 and the lowest is $9.00.
Is RZLT stock a good investment in 2025?
According to current analyst ratings, RZLT has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RZLT stock?
Wall Street analysts predict RZLT stock could reach $13.00 in the next 12 months. This represents a 376.2% increase from the current price of $2.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Rezolute, Inc.'s business model?
Rezolute, Inc. operates in the biotechnology sector, focusing on the research and development of novel therapeutics aimed at treating chronic metabolic diseases and rare liver disorders. The company generates revenue by advancing its innovative pipeline of therapies through clinical trials and eventual commercialization of successful treatments.
What is the highest forecasted price for RZLT Rezolute, Inc.?
The highest price target for RZLT is $16.00 from at , which represents a 486.1% increase from the current price of $2.73.
What is the lowest forecasted price for RZLT Rezolute, Inc.?
The lowest price target for RZLT is $9.00 from Jason Butler at JMP Securities, which represents a 229.7% increase from the current price of $2.73.
What is the overall RZLT consensus from analysts for Rezolute, Inc.?
The overall analyst consensus for RZLT is bullish. Out of 13 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are RZLT stock price projections?
Stock price projections, including those for Rezolute, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
